Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM

Diabetes Care

Volumn 20, Issue 12, 1997, Pages 1880-1886

  Hofmann, Marion A ^a   Kohl, Brigitte ^a   Zumbach, Martina S ^a   Borcea, Valentin ^a   Bierhaus, Angelika ^a   Henkels, Mechthild ^a   Amiral, Jean ^b   Fiehn, Walter ^a   Ziegler, Reinhard ^a   Wahl, Peter ^a   Nawroth, Peter P ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Serbio   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CELL DAMAGE; ENDOTHELIUM CELL; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; OXIDATIVE STRESS; RISK FACTOR; VASCULAR ENDOTHELIUM;

EID: 0030775293     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.12.1880     Document Type: Article

References (52)

1. Vane JR, Angaard EE, Botting RM: Mechanism of disease: regulatory functions of the vascular endothelium. N Engl J Med 323:27-36, 1990
2. Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hacheng WHL, Donker AJM, Ottolander GJH: Urinary albumin excretion, cardiovascular disease and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 340:319-323, 1992
3. Lorenzi M, Cagliero E, Toledo S: Glucose toxicity for human endothelial cells in culture: delayed replication, disturbed cell cycle, and accelerated death. Diabetes 34:621-627, 1985
4. Ceriello A, Russo P, Amstad P, Cerutti P: High glucose induces antioxidant enzymes in human endothelial cells in culture: evidence linking hyperglycemia and oxidative stress. Diabetes 45:471-477, 1996
5. Baynes JW: Role of oxidative stress in development of complications of diabetes. Diabetes 40:405-412, 1991
6. Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care 19:257-267, 1996
7. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D, Schmidt AM: Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy-soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 97:238-243, 1996
8. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96:1395-1403, 1995
9. Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, Zoukourian C, Capron L, Chappey O, Yan SD, Brett J, Guillausseau PJ, Stem D: Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA 91:7742-7746, 1994
10. Schmidt AM, Hasu M, Popov D, Zhang JH, Chen J, Yan SD, Brett J, Cao R, Kuwabara K, Costache G, Simionescu N, Simionescu M, Stem D: Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci USA 91:8807-8811, 1994
11. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
12. Mulec H, Johnsen SA, Wiklund O, Bjorck S: Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kid Dis 22:196-201, 1993
13. Taranov L, Rossing P, Nielsen FS, Hansen BV, Dyerberg J, Parving HH: Increased plasma apolipoprotein(a) levels in IDDM patients with diabetic nephropathy. Diabetes Care 19:1382-1887, 1996
14. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD: Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 98:24-29, 1996
15. Tsai JC, Wang H, Perrella MA, Yoshizumi M, Sibinga NES, Tan LC, Haber E, Chang THTC, Schlegel R, Lee ME: Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 97:146-153, 1996
16. Starkebaum G, Harlan JM: Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 77:1370-1376, 1986
17. Loscalzo J: The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 98:5-7, 1996
18. Stamler JS, Osborne JA, Jaraki O, Mullins M, Single D, Loscalzo J: Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91: 308-311, 1993
19. Hayashi T, Honda G, Suzuki K: An atherogenetic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 79:2930-2936, 1992
20. Lentz SR, Sadler JE: Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 88:1906-1914, 1991
21. Rodgers GM, Conn MT: Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 4:895-901, 1990
22. Esmon CT, Owen WG: Identification of an endothelial cell cofactor for thrombin-catalysed activation of protein C. Proc Natl Acad Sci USA 78:2249-2252, 1981
23. Ishii H, Uchiyama H, Kazama M: Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 65:618-622, 1991
24. Boehme MWJ, Deng Y, Raeth U, Bierhaus A, Ziegler R, Stremmel W, Nawroth PP: Release of thrombomodulin from endothelial cells by concerted action of TNF-α and neutrophils: in vivo and in vitro studies. Immunology 87:134-140, 1996
25. Hemmer CJ, Bierhaus A, van Riedesel J, Gabat S, Liliensiek B, Pitronik P, Lin J, Amiral J, Ziegler R, Schiefer S, Kern P, Seitz R, Dietrich M, Nawroth PP: Elevated thrombomodulin plasma levels as a result of endothelial involvement in P. falciparum malaria. Thromb Haemostas 72:457-464, 1994
26. Gruden G, Pagano G, Romagnoli R, Frenzel D, Olivetti C, Cavallo-Perin P: Thrombomodulin levels in insulin-dependent diabetic patients with microalbuminuria. Diabet Med 12:258260, 1995
27. Semau T, Wilhelm C, Seyfert U, Gabath S, Henkels M, Amiral J, Bergis KH, Ziegler R, Wahl P, Nawroth PP: Thrombomodulin ist ein Marker für mikrovaskulare, aber nicht fur makrovaskulare Endothelzellschadigung. VASA 24:347-353, 1995
28. Oida K, Takai H, Meada H: Plasma thrombomodulin concentration in diabetes mellitus. Diabetes Res Clin Pract 10:193-196, 1990
29. Tanaka A, Ishii M, Hiraishi S, Kamaza M, Meazawa H: Increased thrombomodulin values in plasma of diabetic men with microangiopathy. Clin Chem 37:269-272, 1991
30. Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J: Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 346:85-89, 1995
31. Selhub J, Jaques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH: Association between plasma homocysteine concentration and extracranial carotid-artery stenosis. N Engl J Med 332:286-291, 1995
32. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG: Prospective study of serum total concentration of homocysteine and risk of stroke in middle-aged British men. Lancet 346:1395-1398, 1995
33. van den Berg M, Stehouwer CDA, Bierdrager E, Rauwerda JA: Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol 16:165-172, 1996
34. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 268:877-881, 1992
35. Agardh CD, Agardh E, Andersson A, Hultberg B: Lack of association between plasma homocysteine levels and microangiopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 54:637-641, 1994
36. Hultenberg B, Agardh E, Andersson A, Brattstrom L, Isaksson A, Israelson B, Agardh CD: Increased levels of plasma homocysteine are associated with nephropathy but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 51:277-282, 1991
37. Chauveau P, Chadefaux B, Coude M, Aupetit J, Hannedouche T, Kamoun P, Jungers P: Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kid Int 43 (Suppl. 41):72-77, 1993
38. Bachmann J, Tepel M, Raidt H, Rietzler R, Graefe U, Langer K, Zidek W: Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 6:121-125, 1995
39. Davis MD, Hubbard LD, Tarutmann J: Studies of retinopathy, methodology assessment and classification with fundus photographs. Diabetes 35 (Suppl. 3):42-49, 1985
40. Vester B, Rasmussen K: High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem 29:549-554, 1991
41. Jaffe EA, Nachmann RL, Becker CG, Minick CR: Culture of human endothelial cells derived from umbilical veins: identification by morphologic criteria. J Clin Invest 52:2745-2751, 1973
42. Amundsen T, Ueland PM, Waage A: Plasma homocysteine levels in patients with deep venous thrombosis. Arterioscler Thromb Vasc Biol 15:1321-1323, 1995
43. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM: High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 14:1080-1083, 1994
44. Munshi MN, Stone A, Fink L, Fonseca V: Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism 45:133-135, 1996
45. Borch Johnsen K, Kreiner S: Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J 294:1651-1654, 1987
46. Wall RT, Harlan JM, Harker LA, Striker GE: Homocysteine induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 18:113-121, 1980
47. Harpel PC, Chang VT, Borth W: Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 89:10193-10197, 1989
48. Berg van M, Boers GHJ, Franken DG, Blom HJ, van Kamp GJ, Jakobs C, Ranwerda JA, Klubt C, Stehouwert CDA: Hyperhomocysteinemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 25:176-181, 1995
49. Schienle W, Seitz R, Nawroth P, Rohner I, Lerch L, Krumpholz B, Krauss G, Fowler B, Baumgartner R, Willenbockel U, Egbring R: Thrombomodulin and ristocetincofactor in homocysteinuria: a study in two siblings. Thromb Res 77:79-86, 1995
50. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM: Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 13: 1327-1333, 1993
51. Ubbink JB, Merwe A, Delport R, Allen RH, Stabler SP, Rietzler R, Vermaak WJ: The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 98: 177-184, 1996
52. Guttormsen AB, Ueland PM, Nesthus I, Nygard O, Schneede J, Vollset SE, Refsum H: Derterminants and vitamin responsiveness of intermediate hyperhomocysteinemia (>40 μmol/liter). J Clin Invest 8: 2174-2183